ICUI ICU Medical (ICUI) Insider Trading, Ownership & Congress Trades
Medical Devices · Surgical & medical instruments & apparatus · CIK 0000883984
Form 144 · 7
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
167
13F, latest reported quarter
Conversions, 180 days
7
Codes C/M, not in net · $245.0K priced
What the filings say about ICUI
Insiders, 180 days
-$7.5M net sold
7 sellers · 56% of sales under a 10b5-1 plan
Congress, 1 year
No trades
Last one: sale, 2025-05-06
Planned sales (Form 144), 90 days
$6.6M
7 notices
ICU Medical insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, ICU MEDICAL INC/DE insiders sold a net $7.5M of stock across 114 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 12 earlier Form 4 trades (code P or S) here by this insider (12 sales), the last on May 14, 2026.
- The trade is 12.8% of the 17,258 shares held after it.
- 5 other insiders sold within 30 days.
- 167 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: VP, General Counsel Sanzone Virginia Ruth sold about $369.2K of ICUI under a 10b5-1 plan on Sep 3, 2026; 5 other insiders sold within 30 days and 167 funds added in the latest 13F quarter.Context
- 12 earlier Form 4 trades (code P or S) here by this insider (12 sales), the last on May 14, 2026.
- The trade is 7.7% of the 16,020 shares held after it.
- 5 other insiders sold within 30 days.
- 167 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: VP, General Counsel Sanzone Virginia Ruth sold about $208.5K of ICUI under a 10b5-1 plan on Sep 3, 2026; 5 other insiders sold within 30 days and 167 funds added in the latest 13F quarter.Context
- 12 earlier Form 4 trades (code P or S) here by this insider (12 sales), the last on May 14, 2026.
- The trade is 4.7% of the 15,296 shares held after it.
- 5 other insiders sold within 30 days.
- 167 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: VP, General Counsel Sanzone Virginia Ruth sold about $122.7K of ICUI under a 10b5-1 plan on Sep 3, 2026; 5 other insiders sold within 30 days and 167 funds added in the latest 13F quarter.Context
- 12 earlier Form 4 trades (code P or S) here by this insider (12 sales), the last on May 14, 2026.
- The trade is 4.7% of the 14,604 shares held after it.
- 5 other insiders sold within 30 days.
- 167 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: VP, General Counsel Sanzone Virginia Ruth sold about $118.7K of ICUI under a 10b5-1 plan on Sep 3, 2026; 5 other insiders sold within 30 days and 167 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Aug 31, 2026.
- The trade is 11.4% of the 56,062 shares held after it.
- 5 other insiders sold within 30 days.
- 167 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Bonnell Brian Michael sold about $1.1M of ICUI under a 10b5-1 plan on Sep 1, 2026; 5 other insiders sold within 30 days and 167 funds added in the latest 13F quarter.114 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$7.5M over 180 days
-$6.6M over 90 days
below 83% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
167 funds bought in last quarter
more than 78% of Medical Devices
Revenue
-6.3% year over year
below 85% of Medical Devices
Margin
0.0% net margin
more than 68% of Medical Devices
Buybacks
$8.8M repurchased, FY to 2025-12-31
below 64% of Medical Devices
Short interest
6.2% of the float short (float per yahoo 2026-10-26) · 5.4 days to cover · settled 2026-09-30
more than 70% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch ICUI
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+36.2%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns ICUI: institutional holders (13F)
13F holdings, latest reported quarter
3,753,409 sh
$550.2M
2,781,620 sh
$407.8M
1,470,583 sh
$215.6M
1,298,127 sh
$190.3M
1,123,237 sh
$164.7M
Congress trades in ICUI
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2025-05-06 · disclosed 31 days later
$1,001 - $15,000
Sold 2024-10-31 · disclosed 6 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
ICUI planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
VIRGINIA SANZONE
Filed 2026-09-03
$819.2K
BRIAN BONNELL
Filed 2026-09-01
$1.1M
BRIAN BONNELL
Filed 2026-08-31
$1.6M
DANIEL WOOLSON
Filed 2026-08-13
$982.3K
BENJAMIN SOUSA
Filed 2026-08-12
$401.2K
ICUI mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Janus Henderson Small-Mid Cap Value Fund
$2.3M position · as of 2026-06-30
3.2%
Hartford Schroders US Small Cap Opportunities Fund
$4.7M position · as of 2026-07-31
2.7%
Federated Hermes SDG Engagement Equity Fund
$386.2K position · as of 2026-07-31
2.1%
F/m Emerald Life Sciences Innovation ETF
$2.2M position · as of 2026-05-31
2.1%
AMG River Road Small Cap Value Fund
$18.8M position · as of 2026-07-31
1.9%
Invesco S&P SmallCap Health Care ETF
$2.3M position · as of 2026-05-31
1.8%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Vivek Jain
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$6.5M
$9.2M
$3.2M
-33%
-32%
2024
$6.5M
$23.1M
$3.3M
-17%
-4%
2023
$6.8M
-$8.1M
$3.4M
-47%
+6%
2022
$5.7M
-$11.3M
$2.8M
-16%
-0%
2021
$5.1M
$13.3M
$2.6M
+27%
+52%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $7.5M sold by insiders over 180 days, 167 funds added last quarter, $6.6M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
ICUI financials
Revenue growth
-6.3%
XBRL, annual
Net margin
0.0%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$2.2B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM ICUI
| FY Dec 2025 | $2.2B |
| FY Dec 2024 | $2.4B |
| FY Dec 2023 | $2.3B |
| FY Dec 2022 | $2.3B |
| FY Dec 2021 | $1.3B |
| Jun 2026 | $551.7M |
| Mar 2026 | $530.2M |
| Dec 2025 | $540.7M |
| Sep 2025 | $537.0M |
| Jun 2025 | $548.9M |
| Mar 2025 | $604.7M |
| Dec 2024 | $629.8M |
| Sep 2024 | $589.1M |
At each fiscal year end
Single quarter
Net margin, TTM
+1.4%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM ICUI
| FY Dec 2025 | +0.0% |
| FY Dec 2024 | -4.9% |
| FY Dec 2023 | -1.3% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | +7.8% |
| Jun 2026 | +3.5% |
| Mar 2026 | +5.7% |
| Dec 2025 | -2.9% |
| Sep 2025 | -0.6% |
| Jun 2025 | +6.4% |
| Mar 2025 | -2.6% |
| Dec 2024 | -3.8% |
| Sep 2024 | -5.6% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$152.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM ICUI
| FY Dec 2025 | $91.8M |
| FY Dec 2024 | $124.7M |
| FY Dec 2023 | $82.3M |
| FY Dec 2022 | -$152.4M |
| FY Dec 2021 | $199.0M |
| Jun 2026 | $61.6M |
| Mar 2026 | $27.6M |
| Dec 2025 | $36.0M |
| Sep 2025 | $27.6M |
| Jun 2025 | -$8.5M |
| Mar 2025 | $36.7M |
| Dec 2024 | $16.1M |
| Sep 2024 | $16.2M |
At each fiscal year end
Single quarter
Debt to equity
0.57x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity ICUI
| FY Dec 2025 | 0.60x |
| FY Dec 2024 | 0.81x |
| FY Dec 2023 | 0.77x |
| FY Dec 2022 | 0.79x |
| FY Dec 2021 | 0.00x |
| Jun 2026 | 0.57x |
| Mar 2026 | 0.61x |
| Dec 2025 | 0.60x |
| Sep 2025 | 0.62x |
| Jun 2025 | 0.63x |
| Mar 2025 | 0.77x |
| Dec 2024 | 0.81x |
| Sep 2024 | 0.78x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.19x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt ICUI
| FY Dec 2025 | 0.14x |
| FY Dec 2024 | 0.13x |
| FY Dec 2023 | 0.10x |
| FY Dec 2022 | -0.04x |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.19x |
| Mar 2026 | 0.13x |
| Dec 2025 | 0.14x |
| Sep 2025 | 0.12x |
| Jun 2025 | 0.10x |
| Mar 2025 | 0.14x |
| Dec 2024 | 0.13x |
| Sep 2024 | 0.16x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+1.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity ICUI
| FY Dec 2025 | +0.0% |
| FY Dec 2024 | -5.8% |
| FY Dec 2023 | -1.4% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | +6.6% |
| Jun 2026 | +1.4% |
| Mar 2026 | +2.3% |
| Dec 2025 | +0.0% |
| Sep 2025 | -0.4% |
| Jun 2025 | -1.8% |
| Mar 2025 | -4.6% |
| Dec 2024 | -5.8% |
| Sep 2024 | -5.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+0.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets ICUI
| FY Dec 2025 | +0.0% |
| FY Dec 2024 | -2.7% |
| FY Dec 2023 | -0.7% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | +5.7% |
| Jun 2026 | +0.7% |
| Mar 2026 | +1.1% |
| Dec 2025 | +0.0% |
| Sep 2025 | -0.2% |
| Jun 2025 | -0.9% |
| Mar 2025 | -2.2% |
| Dec 2024 | -2.7% |
| Sep 2024 | -2.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
effective tax rate -4105%, not meaningful
Return on invested capital ICUI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | +9.6% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+2.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed ICUI
| FY Dec 2025 | +1.2% |
| FY Dec 2024 | +1.1% |
| FY Dec 2023 | +0.6% |
| FY Dec 2022 | -1.5% |
| FY Dec 2021 | +7.6% |
| Jun 2026 | +2.0% |
| Mar 2026 | +1.2% |
| Dec 2025 | +1.2% |
| Sep 2025 | +2.0% |
| Jun 2025 | +1.9% |
| Mar 2025 | +1.8% |
| Dec 2024 | +1.1% |
| Sep 2024 | -0.2% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
140.02x
close 2026-10-23 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing ICUI
| FY Dec 2025 | 4,755.67x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 50.07x |
| Jun 2026 | 123.19x |
| Mar 2026 | 69.44x |
| Dec 2025 | 4,755.67x |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$5.2B
market value at close 2026-10-23 on 2026-07-31 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2022-12-31
Enterprise value ICUI
| FY Dec 2025 | $4.6B |
| FY Dec 2024 | $5.2B |
| FY Dec 2023 | $3.8B |
| FY Dec 2022 | $5.2B |
| FY Dec 2021 | $4.5B |
| Jun 2026 | $4.7B |
| Mar 2026 | $4.3B |
| Dec 2025 | $4.6B |
| Sep 2025 | $4.1B |
| Jun 2025 | $4.4B |
| Mar 2025 | $4.7B |
| Dec 2024 | $5.2B |
| Sep 2024 | $5.8B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+3.7%
TTM free cash flow over market value at close 2026-10-23
FCF yield ICUI
| FY Dec 2025 | +2.6% |
| FY Dec 2024 | +3.3% |
| FY Dec 2023 | +3.4% |
| FY Dec 2022 | -4.0% |
| FY Dec 2021 | +3.9% |
| Jun 2026 | +4.2% |
| Mar 2026 | +2.6% |
| Dec 2025 | +2.6% |
| Sep 2025 | +2.4% |
| Jun 2025 | +1.9% |
| Mar 2025 | +3.9% |
| Dec 2024 | +3.3% |
| Sep 2024 | +3.8% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
PEG, trailing ICUI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 2.84x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $2.2B | $2.4B | $2.3B | $2.3B |
| Gross profit | $822.0M | $824.8M | $739.9M | $697.8M |
| Operating income | $42.8M | $43.0M | $22.8M | -$42.9M |
| Net income | $732.0K | -$117.7M | -$29.7M | -$74.3M |
| EPS (diluted) | 0.03 | -4.83 | -1.23 | -3.11 |
| Operating cash flow | $179.8M | $204.0M | $166.2M | -$62.1M |
| Cash | n/a | n/a | n/a | $208.8M |
| Long-term debt | $1.3B | $1.5B | $1.6B | $1.6B |
| Buybacks | $8.8M | $12.0M | $9.3M | $10.9M |
SEC XBRL, fiscal years, as known on 2026-10-27
ICUI Stock Sonar score 6/7 axes
Find similar shapesCompareICUI ranks highest on institutional and government (78th percentile) and profitability (70th), and lowest on insider conviction (12th), among Medical Devices peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
ICUI filings, in plain words
Are ICU Medical insiders buying or selling ICUI?
In the 180 days to 2026-10-27, ICU Medical insiders were net sellers, a net $7.5M across purchases and sales reported on Form 4, by 7 sellers.
Have members of Congress traded ICUI?
Yes, but not in the year to 2026-10-27; the latest on record is a sale by Gilbert Cisneros dated 2025-05-06.
Are there planned insider sales of ICUI?
Yes. 7 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $6.6M of stock; the latest, by VIRGINIA SANZONE, was filed 2026-09-03.
Read the full summary
In the 180 days to 2026-10-27, ICU Medical insiders were net sellers of ICUI, a net $7.5M across purchases and sales reported on Form 4 by 7 sellers. 56% of the 16 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Members of Congress have disclosed trades in ICUI, none in the last year; the latest on record is a sale by Gilbert Cisneros dated 2025-05-06. Insiders filed 7 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $6.6M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
